Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPrEx-DISCOVER Weight Change Study
NL-OMON57532Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing F/TAF cohort, FTC/TDF cohort and Placebo cohort (3 cohorts). Primary endpoint: Weight change and trajectory distributions. Started Jun 2025; status: completed.
02
Drugs
tenofovir alafenamideemtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON57532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57532.